{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T00:18:46Z","timestamp":1788826726277,"version":"build-2803163510"},"reference-count":19,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,8,13]],"date-time":"2025-08-13T00:00:00Z","timestamp":1755043200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["jaadcasereports.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["JAAD Case Reports"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1016\/j.jdcr.2025.08.001","type":"journal-article","created":{"date-parts":[[2025,8,19]],"date-time":"2025-08-19T17:14:30Z","timestamp":1755623670000},"page":"201-205","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Combination therapy including dupilumab, omalizumab, and mycophenolate mofetil for refractory bullous pemphigoid"],"prefix":"10.1016","volume":"65","author":[{"given":"Kayadri","family":"Ratnarajah","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steffie","family":"Ar\u00e8s","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elio","family":"Kechichian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carolina Lucena","family":"Fernandes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"10","key":"10.1016\/j.jdcr.2025.08.001_bib1","doi-asserted-by":"crossref","first-page":"1689","DOI":"10.1111\/jdv.18220","article-title":"Updated S2 K guidelines for the management of bullous pemphigoid initiated by the European Academy of Dermatology and Venereology (EADV)","volume":"36","author":"Borradori","year":"2022","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.jdcr.2025.08.001_bib2","article-title":"Emerging biomarkers and therapeutic strategies for refractory bullous pemphigoid","volume":"12","author":"Zhou","year":"2021","journal-title":"Front Immunol"},{"issue":"1","key":"10.1016\/j.jdcr.2025.08.001_bib3","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.jaad.2020.01.089","article-title":"Dupilumab as a novel therapy for bullous pemphigoid: a multicenter case series","volume":"83","author":"Abdat","year":"2020","journal-title":"J Am Acad Dermatol"},{"issue":"3","key":"10.1016\/j.jdcr.2025.08.001_bib4","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1016\/j.jaci.2008.11.035","article-title":"Pathogenicity of IgE in autoimmunity: successful treatment of bullous pemphigoid with omalizumab","volume":"123","author":"Fairley","year":"2009","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jdcr.2025.08.001_bib5","doi-asserted-by":"crossref","first-page":"2331","DOI":"10.3389\/fimmu.2019.02331","article-title":"The intersection of IgE autoantibodies and eosinophilia in the pathogenesis of bullous pemphigoid","volume":"10","author":"Messingham","year":"2019","journal-title":"Front Immunol"},{"key":"10.1016\/j.jdcr.2025.08.001_bib6","doi-asserted-by":"crossref","first-page":"1506","DOI":"10.3389\/fimmu.2019.01506","article-title":"New insights into the pathogenesis of bullous pemphigoid: 2019 update","volume":"10","author":"Genovese","year":"2019","journal-title":"Front Immunol"},{"issue":"4","key":"10.1016\/j.jdcr.2025.08.001_bib7","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1016\/j.jaci.2020.02.013","article-title":"Autoimmune bullous skin diseases, pemphigus and pemphigoid","volume":"145","author":"Egami","year":"2020","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jdcr.2025.08.001_bib8","doi-asserted-by":"crossref","first-page":"201","DOI":"10.3389\/fmed.2018.00201","article-title":"The role of eosinophils in bullous pemphigoid: a developing model of eosinophil pathogenicity in mucocutaneous disease","volume":"5","author":"Amber","year":"2018","journal-title":"Front Med (Lausanne)"},{"issue":"7","key":"10.1016\/j.jdcr.2025.08.001_bib9","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1111\/all.13131","article-title":"Evidence for a role of eosinophils in blister formation in bullous pemphigoid","volume":"72","author":"de Graauw","year":"2017","journal-title":"Allergy"},{"issue":"1","key":"10.1016\/j.jdcr.2025.08.001_bib10","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.jaad.2019.07.060","article-title":"Pathophysiologic mechanisms of itch in bullous pemphigoid","volume":"83","author":"Hashimoto","year":"2020","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"10.1016\/j.jdcr.2025.08.001_bib11","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1080\/09546634.2019.1689227","article-title":"Dupilumab use in dermatologic conditions beyond atopic dermatitis - a systematic review","volume":"32","author":"Hendricks","year":"2021","journal-title":"J Dermatolog Treat"},{"issue":"10","key":"10.1016\/j.jdcr.2025.08.001_bib12","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1001\/jamadermatol.2018.2526","article-title":"Dupilumab for the treatment of recalcitrant bullous pemphigoid","volume":"154","author":"Kaye","year":"2018","journal-title":"JAMA Dermatol"},{"issue":"11","key":"10.1016\/j.jdcr.2025.08.001_bib13","doi-asserted-by":"crossref","DOI":"10.5070\/D32511046147","article-title":"Dupilumab for bullous pemphigoid with intractable pruritus","volume":"25","author":"Seidman","year":"2019","journal-title":"Dermatol Online J"},{"issue":"10","key":"10.1016\/j.jdcr.2025.08.001_bib14","doi-asserted-by":"crossref","first-page":"1778","DOI":"10.1111\/jdv.13758","article-title":"Successful treatment of bullous pemphigoid with omalizumab as corticosteroid-sparing agent: report of two cases and review of literature","volume":"30","author":"Balakirski","year":"2016","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.jdcr.2025.08.001_bib15","article-title":"Efficacy and safety of dupilumab in moderate-to-severe bullous pemphigoid","volume":"12","author":"Zhang","year":"2021","journal-title":"Front Immunol"},{"issue":"9","key":"10.1016\/j.jdcr.2025.08.001_bib16","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1001\/jamadermatol.2023.2428","article-title":"Evaluation of dupilumab in patients with bullous pemphigoid","volume":"159","author":"Zhao","year":"2023","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.jdcr.2025.08.001_bib17","article-title":"Rituximab, omalizumab, and dupilumab treatment outcomes in bullous pemphigoid: a systematic review","volume":"13","author":"Cao","year":"2022","journal-title":"Front Immunol"},{"issue":"1","key":"10.1016\/j.jdcr.2025.08.001_bib18","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.jaad.2019.03.049","article-title":"Rituximab therapy in patients with bullous pemphigoid: a retrospective study of 20 patients","volume":"81","author":"Polansky","year":"2019","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jdcr.2025.08.001_bib19","article-title":"Case report: combination of omalizumab and dupilumab for recalcitrant bullous pemphigoid","volume":"11","author":"Seyed Jafari","year":"2020","journal-title":"Front Immunol"}],"container-title":["JAAD Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352512625003996?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352512625003996?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,12,9]],"date-time":"2025-12-09T21:35:12Z","timestamp":1765316112000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2352512625003996"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11]]},"references-count":19,"alternative-id":["S2352512625003996"],"URL":"https:\/\/doi.org\/10.1016\/j.jdcr.2025.08.001","relation":{},"ISSN":["2352-5126"],"issn-type":[{"value":"2352-5126","type":"print"}],"subject":[],"published":{"date-parts":[[2025,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Combination therapy including dupilumab, omalizumab, and mycophenolate mofetil for refractory bullous pemphigoid","name":"articletitle","label":"Article Title"},{"value":"JAAD Case Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jdcr.2025.08.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Inc. on behalf of the American Academy of Dermatology, Inc.","name":"copyright","label":"Copyright"}]}}